



## Continuing Education Credit Information

Program Description and Learning Objectives  
Accreditation Information, Types of Credit, Claiming Credit  
Scientific Program  
Disclosures

### Cutting Edge of Transplantation Transplant Summit 2024: Leveraging Innovative Technology To Save and Improve More Lives Through Transplantation

February 22<sup>nd</sup> – February 24<sup>th</sup>, 2024  
Phoenix, AZ

This activity is jointly provided by Global Education Group and American Society of Transplantation



This activity is supported by an educational grants from Bristol Myers Squibb and Veloxis Pharmaceuticals, Inc.

## Program Description and Learning Objectives

### Target Audience

The target audience for CEoT 2024 is primarily clinicians in the field of solid organ transplantation, along with scientists interested in the pragmatic and practical aspects of transplantation. Most of the clinicians in attendance will be medical and surgical directors of transplant programs, nephrologists, hepatologists, as well as heart, lung, and liver transplant professionals. We do anticipate that the focus of this year's meeting will broaden interest and positively impact both attendance and the spectrum of attendees.

### Statement of Need/Program Overview

Technological innovations are expanding rapidly in the field of medicine to improve the delivery of health care. While some of these new technologies are moving into the transplant field, several have yet to become incorporated into standard transplant practice. The overarching goal of the AST Cutting Edge of Transplantation 2024 is to identify those innovative technologies currently being utilized to advance the medical field in general and describe how those technologies could intersect with the practice of transplantation. The conference will 1) address novel, cutting-edge technologies that are being used in general medicine and could be incorporated into the care of transplant patients and 2) define innovative strategies to utilize existing technologies to advance the field of transplantation.

### Meeting Educational Learning Objectives and Welcome Session Learning Objectives:

*After completing this activity, the participant should be better able to:*

1. Define the current advanced technologies available for improving the delivery of medical care to patients.
2. Identify those technologies that have or may have a future role in the care of transplant patients.
3. Describe novel strategies of using currently existing technology to advance the field of transplantation.



4. Discuss the regulatory and ethical challenges associated with the implementation of new technologies in the care of transplant patients.

### **Session 1 Learning Objectives:**

Following this session, attendees should be able to:

1. Describe the impact of new technologies on the transplant patient experience.
2. Describe new technologies impacting or soon to impact the transplant space.
3. Describe new technologies recently adopted in other areas of medicine that have the potential to benefit the transplant space.

### **Session 2 Learning Objectives:**

Following this session, attendees should be able to:

1. Review the fundamental concepts of artificial intelligence and its potential to revolutionize healthcare practices, particularly in the context of transplantation.
2. Discuss current AI applications in solid organ transplantation, examining real-world use cases that range from organ matching and prediction of rejection to treatment optimization and patient outcomes.
3. Discuss the practical implementation of Natural Language Processing (NLP) techniques in the transplantation domain.
4. Explain how AI-driven image analysis, pattern recognition, and medical imaging interpretation are contributing to more accurate diagnostics, preoperative planning, and postoperative assessments.

### **Keynote Session Learning Objectives:**

1. Define the current advanced technologies available for improving the delivery of medical care to patients.
2. Identify those technologies that have or may have a future role in the care of transplant patients.
3. Describe novel strategies of using currently existing technology to advance the field of transplantation.
4. Discuss the regulatory and ethical challenges associated with the implementation of new technologies in the care of transplant patients.

### **Session 4 Learning Objectives:**

Following this session, attendees should be able to:

1. Explain recent advances in artificial intelligence and remote patient monitoring technologies.
2. Define the role of chatbots and their impact on the patient experience.
3. Identify novel medication adherence monitoring technologies.
4. Elucidate ways that innovative technologies can be integrated into clinical practice.

### **Session 6 Kidney Learning Objectives:**

Following this session, attendees should be able to:

1. Describe how virtual rehab can be utilized to help both pre-transplant candidates as well as post-transplant recipients.
2. Review opportunities to explore methods for enhancing communication-integrated patient care through new technologies.
3. Identify how opportunities in improved HLA matching impact organ offers for transplant candidates.



### **Session 6 Liver Learning Objectives:**

Following this session, attendees should be able to:

1. Discuss innovative machine learning models for prediction in transplantation.
2. Review clinical applications of biomarkers in liver transplantation.
3. Examine techniques for viability assessment and therapeutic interventions during machine perfusion.

### **Session 6 Heart Learning Objectives:**

Following this session, attendees should be able to:

1. Describe the most current technologies for ex vivo perfusion and cold static storage.
2. Identify novel biological alternatives to heart transplantation.
3. Describe approved and investigational mechanical circulatory support devices.
4. Elucidate novel ways that molecular tests can enhance heart transplant monitoring.

### **Session 6 Lung Learning Objectives:**

Following this session, attendees should be able to:

1. Describe new technologies for evaluation of peripheral blood specimens that are best suited to assess graft function and predict outcome in lung transplant recipients.
2. Describe new technologies for evaluation of bronchoalveolar lavage specimens that are best suited to assess graft function and predict outcome in lung transplant recipients.
3. Describe new technologies for evaluation of transbronchial biopsy specimens that are best suited to assess graft function and predict outcome in lung transplant recipients.

### **Session 7 Learning Objectives:**

Following this session, attendees should be able to:

1. Describe the field of informatics and how it can improve clinical and system decision making.
2. Identify what decision support systems can do and what considerations need to be taken when implementing.
3. Describe how to integrate analytics and decision support with human processes and decisions to maximize its effectiveness.

### **Session 8 Learning Objectives:**

Following this session, attendees should be able to:

1. Identify the potential ethical challenges integral to implementation of artificial intelligence in transplantation.
2. Categorize potential bias regarding the inputting of data utilized for machine learning and artificial intelligence.
3. Discuss the impact of regulatory constraints on the implementation of innovative technology.

### **Faculty**

Please view the Faculty within the Program Guide at the link [here](#).



**Program Agenda**

Please view the entire program at the link [here](#).

**Physician Accreditation Statement**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and American Society of Transplantation. Global is accredited by the ACCME to provide continuing medical education for physicians.

**Physician Credit Designation**

Global Education Group designates this live activity for a maximum of 9.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**ABIM MOC Recognition Statement**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.75 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**Nursing Continuing Education**

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 9.75 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

**Pharmacist Accreditation Statement**



Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

**Credit Designation**

Global Education Group designates this continuing education activity for 9.75 contact hour(s) (.975 CEUs) of the Accreditation Council for Pharmacy Education.

Please see <https://www.myast.org/cutting-edge-transplantation/2024-meeting-accreditation> for full ACPE information and UAN numbers.

<b>Credit Hours</b>	<b>Date and Time</b>	<b>Title</b>	<b>UAN</b>
.25	2/22/2024 – 1:30 PM-1:45 PM	Welcome Remarks	0530-9999-24-001-L01-P



FEBRUARY 22-24<sup>TH</sup>, 2024 | ARIZONA BILTMORE | PHOENIX, AZ | [www.myAST.org/meetings/CEoT](http://www.myAST.org/meetings/CEoT)

1.0	2/22/2024 – 1:45 PM-2:45 PM	Session 1: Setting the Stage: The Promise of Expanding Technology in Transplantation	0530-9999-24-002-L01-P
1.5	2/22/2024 – 3:15 PM-4:45 PM	Session 2: Artificial Intelligence	0530-9999-24-003-L01-P
1.0	2/23/2024 – 10:15 AM-11:15 AM	Keynote	0530-9999-24-004-L01-P
1.5	2/23/2024 – 1:30 PM-3:00 PM	Session 4: Telemedicine and Remote Patient Monitoring	0530-9999-24-005-L01-P
1.5	2/24/2024 – 8:15 AM-9:45 AM	Session 6: Organ Breakouts 1 - Kidney Transplantation: Leveraging Technology in Getting to a “Yes”	0530-9999-24-006-L01-P
1.5	2/24/2024 – 8:15 AM-9:45 AM	Session 6: Organ Breakouts 2 - Technological Innovations in Liver Transplantation: Enhancing Outcome Prediction and Organ Use	0530-9999-24-007-L01-P
1.5	2/24/2024 – 8:15 AM-9:45 AM	Session 6: Organ Breakouts 3 - Transformation of Heart Transplant through Technological Advancement	0530-9999-24-008-L01-P
1.5	2/24/2024 – 8:15 AM-9:45 AM	Session 6: Organ Breakouts 4 - Beyond Transbronchial Biopsy: New Technologies to Identify Lung Allograft Rejection and Infection	0530-9999-24-009-L01-P
1.5	2/24/2024 – 10:15 AM-11:45 AM	Session 7: Informatics and Decision Support Systems	0530-9999-24-010-L01-P
1.5	2/24/2024 – 2:00 PM-3:30 PM	Session 8: Session 8: Technology Innovations in Transplantation: Ethical, Legal, and Social Challenges	0530-9999-24-011-L01-P

*This is a knowledge-based activity.*

**Global Contact Information**

For information about the accreditation of this program, please contact Global at 303-395-1782 or [cme@globaleducationgroup.com](mailto:cme@globaleducationgroup.com).

**Instructions to Receive Credit**

Following the meeting, all participants will receive a link to an online evaluation form. After completing this evaluation, participants may claim a certificate noting the appropriate amount of credit or request a general certificate of attendance.

For pharmacist learners, partial credit may not be awarded, so sessions must be attended in their entirety to claim credit. Participants requesting pharmacy credit must submit requests for credit within 55 days of participation.

**Fee Information& Refund/Cancellation Policy**

Registration fees were collected for this activity. No refunds are permitted after January 22, 2024.



**Disclosures of Relevant Financial Relationships**

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The **faculty** have the following relevant financial relationships with ineligible companies:

<b>Name of Faculty or Presenter</b>	<b>Reported Financial Relationship</b>
Ali Zarrinpar, MD, PhD	Consulting Fee (e.g., Advisory Board): Natera Speaker's Bureau: CareDx Contracted Research (Principal Investigators must provide information, even if received by the institution): Natera, Paragonix, Regeneron Pharmaceuticals, CareDx, TGI Eurofins, BillionToOne
Alin Gragossian, DO, MPH	Consulting Fee (e.g., Advisory Board): Paragonix Technologies
Allyson Hart, MD, MS	Nothing to disclose
Ana Iltis, PhD	Nothing to disclose
Andrea Schlegel, MD	Speaker's Bureau: Bridge to Life
Andres Duarte-Rojo, MD, MS, DSc	Consulting Fee (e.g., Advisory Board): Axcella Health, Inc Contracted Research (Principal Investigators must provide information, even if received by the institution): Axcella Health, Inc, AMRA Medical, Echosens North America, Inc.
Anoop Sheshadri, MD	Nothing to disclose
Ashley Spann, MD, MSACI	Other: Bristol Myers Squibb Foundation Winn Career Development Grant Award
Benjamin Collins, MD, MS, MA	Nothing to disclose
Catherine Butler, MD, MA	Nothing to disclose
Cory Schaffhausen, MS, PhD	Nothing to disclose
Darren Stewart, MS	Consulting Fee (e.g., Advisory Board): Aditxt, Inc, Veloxis Pharmaceuticals, Inc.
David Page, PhD	Nothing to disclose
Dave Taber, PharmD	Consulting Fee (e.g., Advisory Board): Eurofins Viracor, Inc. Contracted Research (Principal Investigators must provide information, even if received by the institution): CareDx, Merck, Takeda California, Inc., Veloxis Pharmaceuticals, Inc.
David Foley, MD	Consulting Fee (e.g., Advisory Board): eGenesis
Deb Adey, MD	Contracted Research (Principal Investigators must provide information, even if received by the institution): Hansa Biopharma AB, Natera



Debbie Levine, MD	Nothing to disclose
Demilade Adedinsewo, MD, MPH	Nothing to disclose
Earnest Davis	Nothing to disclose
Gary Weissman, MD, MSHP	Nothing to disclose
Jesse Ehrenfeld, MD, MPH	Consulting Fee (e.g., Advisory Board): Augmedix
Jesse Schold, PhD, MStat, MEd	Consulting Fee (e.g., Advisory Board): Sanofi US Services, Inc., Veloxis Pharmaceuticals, Inc., eGenesis, Novartis Other: Data Monitoring and Safety Board Member for studies with: Bristol-Myers Squibb, NextCure, CSL-Behring
Jim Rodrigue, PhD	Nothing to disclose
Joe Gaut, MD, PhD	Nothing to disclose
John Belperio, MD	Nothing to disclose
John Greenland, MD, PhD	Consulting Fee (e.g., Advisory Board): Mallinckrodt, Theravance Biopharma Inc. Contracted Research (Principal Investigators must provide information, even if received by the institution): Mallinckrodt, Theravance Biopharma Inc.
Jon Kobashigawa, MD	Nothing to disclose
Josef Stehlik, MD, MPH	Consulting Fee (e.g., Advisory Board): Medtronic USA, Inc., Natera, Transmedics Contracted Research (Principal Investigators must provide information, even if received by the institution): Merck, Natera
Joseph Hillenburg	Nothing to disclose
Josh Levitsky	Consulting Fee (e.g., Advisory Board): eGenesis, Eurofins Viracor, Inc., Mallinckrodt LLC Contracted Research (Principal Investigators must provide information, even if received by the institution): Novartis Speakers' Bureau: Takeda Pharmaceutical Company Other: Data and Safety Monitoring - Quell
Kiran Khush, MD, MAS	Consulting Fee (e.g., Advisory Board): CareDx, Inc.
Kristopher Croome, MD	Nothing to disclose
Leo Anthony Celi, MD, MPH, MSc	Consulting Fee (e.g., Advisory Board): Philips
Lisa Cantwell	Nothing to disclose
Lisa McElroy, MD, MS	Nothing to disclose
Loren Gragert, PhD, A(ACHI)	Nothing to disclose
Mamatha Bhat, MD, MSc, PhD, FRCPC	Consulting Fee (e.g., Advisory Board): Novartis, Paladin Contracted Research (Principal Investigators must provide information, even if received by the institution): Transplant Genomics, Natera, Novo Nordisk
Marina Serper, MD	Contracted Research (Principal Investigators must provide information, even if received by the institution): Grifols Biologicals, Inc.
Megan Levings, PhD	Other: Patent pending through University of British Columbia School of Bioengineering
Melana Yuzefpolskaya, MD	Nothing to disclose
Melissa McQueen	Contracted Research (Principal Investigators must provide information, even if received by the institution): CareDx, Natera



Molly McCarthy	Nothing to disclose
Rachel Patzer, PhD MPH	Nothing to disclose
Roslyn Mannon, MD, FAST, FASN	Consulting Fee (e.g., Advisory Board): Chinook Therapeutics, CSL Behring, HI-Bio, Natera, Sanofi and Genzyme US Companies, VericiDx Contracted Research (Principal Investigators must provide information, even if received by the institution): VericiDx
Roy Bloom, MD	Contracted Research (Principal Investigators must provide information, even if received by the institution): CSL Behring, Natera, Veloxis Pharmaceuticals, Inc. Stock Shareholder: Gilead Sciences, Inc.
Sandra Amaral, MD, MHS	Other: Data and Safety Monitoring for Bristol-Myers Squibb
Sean Pinney, MD	Consulting Fee (e.g., Advisory Board): Ancora Heart, Inc., Boston Scientific Corporation, CareDx, Cordio, Medtronic USA, Inc., Procyron, Restore Medical, Valgen Medtech Other: Data And Safety Monitoring, Transmedics Other: End Point Review Committee, Abbott Laboratories
Stephen Juvet, MD, PhD	Consulting Fee (e.g., Advisory Board): BlueRock Therapeutics Contracted Research (Principal Investigators must provide information, even if received by the institution): Boehringer Ingelheim, Sanofi Pasteur, Inc.
Steven Hays, MD	Consulting Fee (e.g., Advisory Board): AI Therapeutics, Inc., CareDx, Mallinckrodt Hospital Products Inc.
Stuart Knechtle, MD	Contracted Research (Principal Investigators must provide information, even if received by the institution): Alexion, eGenesis, Visterra
Stuart Sweet, MD, PhD	Nothing to disclose
Sumit Mohan, MD	Nothing to disclose
Susie Joseph, MD	Nothing to disclose
Tiffany Kaiser, PharmD	Consulting Fee (e.g., Advisory Board): Eurofins Transplant Genomics
Valeria Mas, PhD	Nothing to disclose
Victoria Palafox, RN	Nothing to disclose
Vineeta Kumar, MD, FAST	Consulting Fee (e.g., Advisory Board): Veloxis Pharmaceuticals, Inc. Contracted Research (Principal Investigators must provide information, even if received by the institution): United Therapeutics Corporation

The **planners and managers** have the following relevant financial relationships with ineligible companies:

<b>Name of Planner or Manager</b>	<b>Reported Financial Relationship</b>
Rhys Williams, MSN, FNP-C, RN	Nothing to disclose
Conor Hughes	Nothing to disclose
Amanda Glazar	Nothing to disclose
Andrea Funk	Nothing to disclose
Liddy Knight	Nothing to disclose





Ashley Cann	Nothing to disclose
Lauren Sinclair	Nothing to disclose
Deborah Sharkey	Nothing to disclose
Charlotte Aguilar	Nothing to disclose
JoAnn Gwynn	Nothing to disclose
Annabella Lee	Nothing to disclose
Emerson Steffe	Nothing to disclose
Katherine Hamilton	Nothing to disclose
Jennifer Gillespie	Nothing to disclose

**Disclosure of Unlabeled Use**

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and American Society of Transplantation do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

**Disclaimer**

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.